403 related articles for article (PubMed ID: 25818308)
1. Biosimilar monoclonal antibodies in lymphoma: a critical appraisal.
Rioufol C; Salles G
Expert Rev Anticancer Ther; 2015 May; 15(5):569-78. PubMed ID: 25818308
[TBL] [Abstract][Full Text] [Related]
2. Scientific rationale for extrapolation of biosimilar data across cancer indications: case study of CT-P10.
Ogura M; Coiffier B; Kwon HC; Yoon SW
Future Oncol; 2017 May; 13(15s):45-53. PubMed ID: 28482699
[TBL] [Abstract][Full Text] [Related]
3. A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera
Sharman JP; Liberati AM; Ishizawa K; Khan T; Robbins J; Alcasid A; Rosenberg JA; Aurer I
BioDrugs; 2020 Apr; 34(2):171-181. PubMed ID: 31820339
[TBL] [Abstract][Full Text] [Related]
4. Rituximab biosimilars for lymphoma in Europe.
Jurczak W; Długosz Danecka M; Buske C
Expert Opin Biol Ther; 2019 Oct; 19(10):1045-1056. PubMed ID: 31512535
[No Abstract] [Full Text] [Related]
5. CT-P10 (Truxima™): A Rituximab Biosimilar.
Deeks ED
BioDrugs; 2017 Jun; 31(3):275-278. PubMed ID: 28497220
[TBL] [Abstract][Full Text] [Related]
6. Clinical development of CT-P10 and other biosimilar cancer therapeutics.
Kim WS; Coiffier B; Kwon HC; Kim S
Future Oncol; 2017 May; 13(15s):31-44. PubMed ID: 28482700
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, efficacy and safety of the rituximab biosimilar CT-P10.
Coiffier B
Expert Rev Clin Pharmacol; 2017 Sep; 10(9):923-933. PubMed ID: 28766389
[TBL] [Abstract][Full Text] [Related]
8. An introduction to biosimilar cancer therapeutics: definitions, rationale for development and regulatory requirements.
Buske C; Ogura M; Kwon HC; Yoon SW
Future Oncol; 2017 May; 13(15s):5-16. PubMed ID: 28482702
[TBL] [Abstract][Full Text] [Related]
9. A review of the totality of evidence in the development of ABP 798, a rituximab biosimilar.
Cobb P; Niederwieser D; Cohen S; Hamm C; Burmester G; Seo N; Lehto SG; Hanes V
Immunotherapy; 2022 Jun; 14(9):727-740. PubMed ID: 35543293
[TBL] [Abstract][Full Text] [Related]
10. The Ecstacy of Gold: Patent Expirations for Trastuzumab, Bevacizumab, Rituximab, and Cetuximab.
Serna-Gallegos TR; La-Fargue CJ; Tewari KS
Recent Pat Biotechnol; 2018; 12(2):101-112. PubMed ID: 29173192
[TBL] [Abstract][Full Text] [Related]
11. Biosimilar monoclonal antibodies: A Canadian regulatory perspective on the assessment of clinically relevant differences and indication extrapolation.
Scott BJ; Klein AV; Wang J
J Clin Pharmacol; 2015 Mar; 55 Suppl 3():S123-32. PubMed ID: 24965228
[TBL] [Abstract][Full Text] [Related]
12. Biosimilar monoclonal antibodies: preclinical and clinical development aspects.
Gonçalves J; Araújo F; Cutolo M; Fonseca JE
Clin Exp Rheumatol; 2016; 34(4):698-705. PubMed ID: 27383278
[TBL] [Abstract][Full Text] [Related]
13. Comparative Efficacy and Safety of Biosimilar Rituximab and Originator Rituximab in Rheumatoid Arthritis and Non-Hodgkin's Lymphoma: A Systematic Review and Meta-analysis.
Lee S; Lee H; Kim E
BioDrugs; 2019 Oct; 33(5):469-483. PubMed ID: 31446557
[TBL] [Abstract][Full Text] [Related]
14. In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis.
Salinas-Jazmín N; González-González E; Vásquez-Bochm LX; Pérez-Tapia SM; Velasco-Velázquez MA
J Vis Exp; 2017 May; (123):. PubMed ID: 28518088
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
[TBL] [Abstract][Full Text] [Related]
16. The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis.
Braun J; Kay J
Expert Opin Drug Saf; 2017 Mar; 16(3):289-302. PubMed ID: 28068848
[TBL] [Abstract][Full Text] [Related]
17. GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies.
Robak T
Curr Opin Investig Drugs; 2009 Jun; 10(6):588-96. PubMed ID: 19513948
[TBL] [Abstract][Full Text] [Related]
18. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
[TBL] [Abstract][Full Text] [Related]
19. Rituximab: review and clinical applications focusing on non-Hodgkin's lymphoma.
King KM; Younes A
Expert Rev Anticancer Ther; 2001 Aug; 1(2):177-86. PubMed ID: 12113023
[TBL] [Abstract][Full Text] [Related]
20. Looking to the future and learning lessons from the recent past: changing stakeholder perceptions of biosimilars in cancer.
Kim WS; Ogura M; Kwon HC; Choi D
Future Oncol; 2017 May; 13(15s):17-29. PubMed ID: 28482701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
